Literature DB >> 9331164

Protease activity in a hapten-induced model of ulcerative colitis in rats.

J V Hawkins1, E L Emmel, J J Feuer, M A Nedelman, C J Harvey, H J Klein, H Rozmiarek, A R Kennedy, G R Lichtenstein, P C Billings.   

Abstract

Inflammatory bowel disease (IBD) is a painful and debilitating condition affecting the mucosal lining of the colon and other areas of the gastrointestinal tract. IBD generally falls into two major categories: ulcerative colitis (UC) and Crohn's disease. We have utilized dinitrobenzenesulfonic acid (DNBS) to induce experimental UC in rats. Histopathologic analysis indicates that DNBS induces a condition in animals similar to human UC. Biochemical results revealed 6- to 10-fold elevated levels of serine protease activity in colon tissue from animals with UC as compared with matched controls. We also observed elevated levels of protease activity in tissue samples obtained from human patients with UC. Hence, our results demonstrate that protease activity is increased in rodent and human UC. These proteases may play a significant role in destruction of colonic tissue in IBD. Protease inhibitors that target serine proteases may be useful pharmacological agents to limit tissue destruction in IBD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331164     DOI: 10.1023/a:1018887832465

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease.

Authors:  M Bohe; S Genell; K Ohlsson
Journal:  Scand J Gastroenterol       Date:  1986-06       Impact factor: 2.423

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  [Bowman-Birk soy inhibitor as an affinity ligand for isolating leukocyte elastase. Inhibition of elastin hydrolysis, catalyzed by leukocyte elastase].

Authors:  T V Tikhonova; N I Larionova; I P Gladysheva; N F Kazanskaia
Journal:  Biokhimiia       Date:  1993-11

Review 4.  Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review.

Authors:  J Brynskov; O H Nielsen; I Ahnfelt-Rønne; K Bendtzen
Journal:  Dig Dis       Date:  1994 Sep-Oct       Impact factor: 2.404

5.  The ability of hapten-conjugated cells to induce cell-mediated cytotoxicity is affected by the mode of hapten linkage.

Authors:  F Nahas; S Leskowitz
Journal:  Cell Immunol       Date:  1980-08-15       Impact factor: 4.868

6.  A growth-regulated protease activity that is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor.

Authors:  P C Billings; J M Habres
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

7.  Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis.

Authors:  M Bohe
Journal:  Scand J Gastroenterol       Date:  1987-01       Impact factor: 2.423

8.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

9.  Influence of inflammatory bowel disease on the distribution and concentration of pancreatic secretory trypsin inhibitor within the colon.

Authors:  R J Playford; A M Hanby; K Patel; J Calam
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

10.  Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine.

Authors:  P C Billings; P M Newberne; A R Kennedy
Journal:  Carcinogenesis       Date:  1990-07       Impact factor: 4.944

View more
  18 in total

1.  Damage to the enteric nervous system in experimental colitis.

Authors:  S Sanovic; D P Lamb; M G Blennerhassett
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis.

Authors:  Gary R Lichtenstein; Julius J Deren; Seymour Katz; James D Lewis; Ann R Kennedy; Jeffrey H Ware
Journal:  Dig Dis Sci       Date:  2007-06-06       Impact factor: 3.199

3.  The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis.

Authors:  J F Tarlton; C V Whiting; D Tunmore; S Bregenholt; J Reimann; M H Claesson; P W Bland
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Relation between colonic inflammation severity and total low-molecular-weight antioxidant profiles in experimental colitis.

Authors:  S Blau; R Kohen; P Bass; A Rubinstein
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

5.  Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis.

Authors:  Joshua-Ka-Shun Ko; Flora-Ying-Lee Lam; Andrew-Pok-Lap Cheung
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

6.  Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.

Authors:  J H Ware; X S Wan; P Newberne; A R Kennedy
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

7.  Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis.

Authors:  Kailash C Bhol; Paul J Schechter
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

Review 8.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.

Authors:  Kristina K Hansen; Katerina Oikonomopoulou; Yang Li; Morley D Hollenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

9.  Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis.

Authors:  A Ukil; S Maity; S Karmakar; N Datta; J R Vedasiromoni; Pijush K Das
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

10.  Soluble CD83 ameliorates experimental colitis in mice.

Authors:  J Eckhardt; S Kreiser; M Döbbeler; C Nicolette; M A DeBenedette; I Y Tcherepanova; C Ostalecki; A J Pommer; C Becker; C Günther; E Zinser; T W Mak; A Steinkasserer; M Lechmann
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.